BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND LDH AND Prognosis
58 results:

  • 1. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
    Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
    Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
    Beypınar I; Sözel Y; Önder AH
    Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma.
    Du KX; Shen HR; Pan BH; Luthuli S; Wang L; Liang JH; Li Y; Yin H; Li JY; Wu JZ; Xu W
    Clin Transl Oncol; 2024 Mar; 26(3):720-731. PubMed ID: 37558851
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Outcomes in patients with
    Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
    Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
    Pelizzari G; Bertoli E; Buriolla S; Vitale MG; Basile D; Palmero L; Zara D; Iacono D; Andrea F; Pascoletti G; Bolzonello S; Garutti M; Fasola G; Puglisi F; Minisini AM
    Melanoma Res; 2023 Oct; 33(5):398-405. PubMed ID: 37402350
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
    Dutriaux C; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Saiag P
    Eur J Cancer; 2022 Nov; 175():254-262. PubMed ID: 36170791
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clinical predictors of survival in real world practice in stage IV melanoma.
    Hu HP; Archer C; Yip D; Peters G
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1691. PubMed ID: 36161287
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Lactate dehydrogenase as promising marker for prognosis of brain metastasis.
    Pei YY; Zhang Y; Liu ZR; He Y; Yu JY; Zhang RJ; Wang JJ; Peng XC; Fang F
    J Neurooncol; 2022 Sep; 159(2):359-368. PubMed ID: 35794505
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
    He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
    Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Preoperative serum lactate dehydrogenase level predicts progression and prognosis in patients with glioma.
    Chen XY; Chen JY; Chen Y; Chen JF; Lin N; Ding CY; Kang DZ; Wang DL; Fang WH
    Clin Neurol Neurosurg; 2021 Oct; 209():106912. PubMed ID: 34509141
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
    van der Meulen M; Dirven L; Bakunina K; van den Bent MJ; Issa S; Doorduijn JK; Bromberg JEC
    J Neurooncol; 2021 Apr; 152(2):357-362. PubMed ID: 33611761
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pretreatment age and serum lactate dehydrogenase as predictors of synchronous second primary cancer in patients with nasopharyngeal carcinoma.
    Yeh CF; Ho CY; Chin YC; Shu CH; Chao YT; Lan MY
    Oral Oncol; 2020 Nov; 110():104990. PubMed ID: 32932171
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Real-world outcomes of advanced melanoma patients not represented in phase III trials.
    van Zeijl MCT; Ismail RK; de Wreede LC; van den Eertwegh AJM; de Boer A; van Dartel M; Hilarius DL; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Haanen JBAG; Wouters MWJM
    Int J Cancer; 2020 Dec; 147(12):3461-3470. PubMed ID: 32559817
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors.
    Shen N; Wang Y; Sun X; Bai X; He J; Cui Q; Qian J; Zhu H; Chen Y; Xing R; Liu Q; Wu Y; Li J; Lai W; Sun S; Ji N; Liu Y
    Brain Behav; 2020 Aug; 10(8):e01718. PubMed ID: 32533646
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]    [Full Text] [Related]  

  • 19. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
    Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
    BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy.
    Anami S; Doi H; Nakamatsu K; Uehara T; Wada Y; Fukuda K; Inada M; Ishikawa K; Kanamori S; Nishimura Y
    J Radiat Res; 2019 Mar; 60(2):257-263. PubMed ID: 30576550
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.